Insmed (INSM) said Thursday that the US Food and Drug Administration accepted its new drug application for brensocatib to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition.
The US regulator granted priority review to the new drug application and has set a target action date of Aug. 12, according to the company.
The application is based on data from the phase 3 Aspen study that showed brensocatib, at both doses tested, significantly reduced lung flare-ups and lowered lung function decline compared to a placebo over one year, Ismed added.
The company said it plans to file regulatory submissions for brensocatib in the European Union, UK and Japan in 2025.
Price: 81.00, Change: -0.44, Percent Change: -0.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.